{"id":55929,"date":"2023-04-18T10:03:22","date_gmt":"2023-04-18T08:03:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/"},"modified":"2023-04-18T10:03:22","modified_gmt":"2023-04-18T08:03:22","slug":"orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/","title":{"rendered":"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries"},"content":{"rendered":"
\n

PARIS & CHARLOTTE, N.C.–(BUSINESS WIRE)–ORPHELIA Pharma<\/a>, a French biopharmaceutical company dedicated to the development and marketing of pediatric and orphan medicines, and Tanner Pharma Group<\/a>, a global provider of integrated specialty access solutions, have signed an exclusive agreement to manage the supply and distribution of Ped-TMZ, also known as KIMOZO\u00ae (temozolomide 40 mg\/ml, oral suspension), to meet the special demands which may come from physicians for this unapproved pediatric form of temozolomide.<\/p>\n

<\/a><\/p>\n

\nTemozolomide is an anti-cancer drug approved as capsules or IV formulation in Europe for certain brain tumors. It is also used in treatment protocols for other rare cancer indications that mainly affect very young children, including refractory or relapsed neuroblastoma. In young children, an oral suspension of temozolomide is age-appropriate to ensure correct medication administration.<\/p>\n

\nUnder the terms of the agreement, Tanner Pharma will provide access to KIMOZO\u00ae via a named patient program in European countries, in particular countries where KIMOZO\u00ae has already been used as an investigational medication in the context of ORPHELIA Pharma’s now fully enrolled TEMOkids clinical trial. A named patient program is a mechanism through which physicians can legally and ethically prescribe investigational or approved drugs for patients prior to their commercial availability. The access to unapproved drugs is strictly regulated and adherence to national regulations is mandatory.<\/p>\n

\nTanner Pharma will manage all elements of the supply including healthcare practitioner enquiry management, national regulatory oversight, liaison with national authorities, and logistics. The agreement currently covers all European territories but France.<\/p>\n

\nHealthcare professionals <\/b>can obtain details about the program by contacting: kimozo@tannerpharma.com<\/a>.<\/p>\n

\nAbout KIMOZO\u00ae 40 mg\/ml<\/b><\/p>\n

\nKIMOZO\u00ae 40 mg\/ml is a liquid, taste-masked and ready-to-use drinkable formulation of temozolomide developed in collaboration between the pharmacists and clinicians of Gustave Roussy hospital and the development team of ORPHELIA Pharma. KIMOZO\u00ae is being developed for the treatment of refractory and relapsed neuroblastoma, a childhood cancer of dismal prognosis.<\/p>\n

\nKIMOZO\u00ae was granted Early Access Authorisation (Autorisation d\u2019Acc\u00e8s Pr\u00e9coce) by the French authorities in March 2022.<\/p>\n

\nThe formulation of KIMOZO\u00ae is covered by a patent application in Europe and in the US.<\/p>\n

\nFor more information about ORPHELIA Pharma, visit <\/b>www.orphelia-pharma.eu<\/a><\/b>.<\/b><\/p>\n

\nFor more information about Tanner Pharma Group, visit <\/b>www.tannerpharma.com<\/a><\/b>.<\/b><\/p>\n

Contacts<\/b> <\/p>\n

\nORPHELIA Pharma
\n
Magali Rosbif
\n
Tel: +33 (0)1 42 77 08 18
\n
orphelia@orphelia-pharma.eu<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PARIS & CHARLOTTE, N.C.–(BUSINESS WIRE)–ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric and orphan medicines, and Tanner Pharma Group, a global provider of integrated specialty access solutions, have signed an exclusive agreement to manage the supply and distribution of Ped-TMZ, also known as KIMOZO\u00ae (temozolomide 40 mg\/ml, oral suspension), … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55929","6":"format-standard","7":"category-industry"},"yoast_head":"\nORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PARIS & CHARLOTTE, N.C.–(BUSINESS WIRE)–ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric and orphan medicines, and Tanner Pharma Group, a global provider of integrated specialty access solutions, have signed an exclusive agreement to manage the supply and distribution of Ped-TMZ, also known as KIMOZO\u00ae (temozolomide 40 mg\/ml, oral suspension), ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T08:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230418005094\/en\/1763554\/21\/orphelia-pharma.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries\",\"datePublished\":\"2023-04-18T08:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/\"},\"wordCount\":399,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005094\\\/en\\\/1763554\\\/21\\\/orphelia-pharma.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/\",\"name\":\"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005094\\\/en\\\/1763554\\\/21\\\/orphelia-pharma.jpg\",\"datePublished\":\"2023-04-18T08:03:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005094\\\/en\\\/1763554\\\/21\\\/orphelia-pharma.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005094\\\/en\\\/1763554\\\/21\\\/orphelia-pharma.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/","og_locale":"en_US","og_type":"article","og_title":"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries - Pharma Trend","og_description":"PARIS & CHARLOTTE, N.C.–(BUSINESS WIRE)–ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric and orphan medicines, and Tanner Pharma Group, a global provider of integrated specialty access solutions, have signed an exclusive agreement to manage the supply and distribution of Ped-TMZ, also known as KIMOZO\u00ae (temozolomide 40 mg\/ml, oral suspension), ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-18T08:03:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230418005094\/en\/1763554\/21\/orphelia-pharma.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries","datePublished":"2023-04-18T08:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/"},"wordCount":399,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005094\/en\/1763554\/21\/orphelia-pharma.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/","url":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/","name":"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005094\/en\/1763554\/21\/orphelia-pharma.jpg","datePublished":"2023-04-18T08:03:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230418005094\/en\/1763554\/21\/orphelia-pharma.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230418005094\/en\/1763554\/21\/orphelia-pharma.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/orphelia-pharma-selects-tanner-pharma-group-to-initiate-named-patient-program-for-kimozo-temozolomide-in-european-countries\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO\u00ae (temozolomide) in European Countries"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55929"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55929\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}